Physician Views: With Januvia data looming, what impact will FDA AdComm have on use of DPP-IV inhibitors?

Physician Views: With Januvia data looming, what impact will FDA AdComm have on use of DPP-IV inhibitors?

Code: FW-20150409 | Published: Apr-2015 | Pages: - | FirstWord
Price :
$695.00
USD

* Required Fields

$695.00

Details






Lingering concerns have been hanging over AstraZenecas Onglyza and Takedas Nesina since 2013 when detailed analyses from respective cardiovascular (CV) outcomes studies suggested the DPP-IV inhibitors may be associated with an increased risk of heart failure.

On April 14, the FDAs Endocrinologic and Metabolic Drugs Advisory Committee finally provided some semblance of closure to the matter when it voted overwhelmingly in favour of changing the labels of both drugs to include new warning information about the possible heart failure risk.

Rather than be hurt by the recommendation though, Takeda and (especially) AstraZeneca were able to let out small sighs of relief that the worst case scenario - however improbable - of market withdrawals had been avoided, along with the slightly more possible scenario where use of the drugs would be restricted to certain patients. (See ViewPoints: Handicapping potential outcomes from Tuesdays FDA meeting to discuss safety of DPP-IV inhibitors.)

One wildcard looming over the proceedings is the ongoing CV outcomes study (TECOS) evaluating Merck & Co.s Januvia, the market-leading DPP-IV inhibitor, which will play a key role in determining whether the heart failure signal is deemed to be a class effect and, more importantly, what impact it will have on use of the three medicines - and each individually.

Waiting in the wings for any possible fallout from the increased scrutiny on DPP-IV inhibitors are agents in classes like the SGLT2 inhibitors, which analysts suggest could gain an increased share of the market should physicians shy away from Januvia, Onglyza and/or Nesina.








To gain better understanding about the impact of the FDA panels discussion and recommendations, FirstWord PLUS is polling US- and EU5-based endocrinologists and asking them




- An FDA panel voted to add safety information about the risk of heart failure to labels for Onglyza and Nesina. With data from a cardiovascular (CV) outcomes trial of Januvia still to come (expected in June), what impact will the panel vote have on your overall use of DPP-IV inhibitors?
- Januvia is by far the most prescribed DPP-IV inhibitor, followed by Onglyza and Nesina a distant third. The FDA briefing documents and panel discussion seemed to suggest Nesinas CV profile might be slightly more benign than that of Onglyza. Will this have any impact on your use of individual DPP-IV inhibitors?
- Assuming Januvias cardiovascular safety profile looks roughly in-line with Onglyza/Nesina, how will that impact your overall use of DPP-IV inhibitors?
- If, on the other hand, Januvias cardiovascular safety profile looks better than that of Onglyza/Nesina, how would that impact your prescribing of Januvia ?
- Given the increased scrutiny of DPP-IV safety, might you be more likely to reach for another therapeutic modality rather than a DPP-IV inhibitor?





Report Format

Following are different modes of Licenses.

a. Single User License:
This license allows only one person to use the report. This person can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people. Unless you purchase a Site License or a Global Site License, a Single User License must be purchased for every single person that wishes to use the report within the same enterprise.

b. Single Site License:
This license allows unlimited users to use the report within one company location, e.g. a regional office. These users can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people.

c. Global Site License:
A Global Site License (or Enterprise wide Site License or Global License) is a license granted to original purchaser, who can share a report with other employees and authorized Users of the same organization.

Quick Help

1. How do you deliver the reports?
The delivery of reports is depends on format & mode of license of report(s). Following are different kinds of formats of report(s) and their delivery options :

a. Electronic Format – Through email from Publisher
Report will be sent to your username email address in PDF, Excel, PowerPoint or any other electronic / softcopy format by publisher.
Delivery Time: 12 to 48 hours [depending on time difference or occurrences of national holidays]

b. Hard Copy or Printed Format or CD-Rom – Through Mail or Courier from Publisher
Report will be sent through mail / courier delivery to your shipping address by publisher.
Delivery Time: Less than, few weeks [depending on time difference or occurrences of national holidays]


2. How can I make payment for publications I purchase?
You could be able to make the payment, in following ways:

a. Online Secure Payment through Credit Card Payment : We accept Visa, Master, AMEX Cards & CCAvenue
b. Transfer of fund to our bank account via Bank transfer or Wire transfer
c. Payment via DD or Cheque
d. Paypal


3. Is it safe to use my credit card on MarketinfoResearch?
Your personal information and online tranaction on Marketinfo Research is secure, private, and tamper-proof. All credit card payments are processed through secure and trusted payment gateways.

If you have a more question about our publications please see our FAQs section or contact us now at cs@marketinforesearch.com.

CUSTOMERS WHO VIEWED THIS REPORT ALSO VIEWED

There are no reports matching the selection.

Browse similar reports by category:
Pharmaceuticals & Healthcare
FirstWord